These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2876689)

  • 1. Pharmacological effects of nalorphine and nalorphine-7,8-oxide (nalorphine-epoxide): interaction of the intrinsic activity, affinity and pharmacological responses.
    Konno F; Kobayashi C; Morimoto R; Takayanagi I; Cho N; Hirobe M
    Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):219-32. PubMed ID: 2876689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic activity and effects of guanyl-5'-yl imidodiphosphate, Gpp(NH)p and sodium ion on the affinity of dynorphin 1-13, nalorphine and nalorphine-7,8-oxide to kappa-opioid receptor.
    Takayanagi I; Okumura K; Konno F; Koike K; Cho N; Hirobe M
    Gen Pharmacol; 1985; 16(6):617-9. PubMed ID: 2867951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kappa-receptor mechanisms in synaptosomal Ca uptake.
    Toru T; Konno F; Takayanagi I; Hirobe M
    Gen Pharmacol; 1989; 20(2):249-52. PubMed ID: 2565850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible blockade of the kappa-receptor by a newly synthesized dynorphin derivative containing a 3-nitro-2-pyridinesulfenyl group.
    Koike K; Takayanagi I; Hirakura Y; Matsueda R
    Arch Int Pharmacodyn Ther; 1991; 313():33-46. PubMed ID: 1687773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia.
    Pasternak GW
    Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3691-4. PubMed ID: 6251477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kappa opioid properties of dynorphin and its peptide fragments on the guinea-pig Ileum.
    Yoshimura K; Huidobro-Toro JP; Lee NM; Löh HH; Way EL
    J Pharmacol Exp Ther; 1982 Jul; 222(1):71-9. PubMed ID: 6123594
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterogeneity of opioid receptor binding in brain slices.
    Barchfeld-Rothschild CC; Medzihradsky F
    J Neurosci Res; 1987; 18(2):358-65. PubMed ID: 2891857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of codeine-7,8-oxide (codeine-epoxide), as a new metabolite of codeine, with multiple opiate receptors.
    Konno F; Sato Y; Togashi K; Takayanagi I; Hirobe M
    Gen Pharmacol; 1985; 16(4):379-81. PubMed ID: 2995195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM; Leander JD; Reel JK; Hynes MD
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
    De Souza EB; Schmidt WK; Kuhar MJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative stimulus properties of nalorphine in the rhesus monkeys.
    Tang AH; Code RA
    J Pharmacol Exp Ther; 1983 Dec; 227(3):563-9. PubMed ID: 6317838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo receptor binding of opioid drugs at the mu site.
    Rosenbaum JS; Holford NH; Sadée W
    J Pharmacol Exp Ther; 1985 Jun; 233(3):735-40. PubMed ID: 2989495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of rat brain opioid receptors by cannabinoids.
    Vaysse PJ; Gardner EL; Zukin RS
    J Pharmacol Exp Ther; 1987 May; 241(2):534-9. PubMed ID: 3033219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some pharmacological properties of a newly synthesized morphine derivative, (-)-6 beta-acetylthiomorphine.
    Takayanagi I; Konno F; Goromaru N; Koike K; Kanematsu K; Fujii I; Togame H
    Arch Int Pharmacodyn Ther; 1988; 294():71-84. PubMed ID: 3069065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of three opiate receptor binding sites with the use of a computerized curve-fitting technique.
    Pfeiffer A; Herz A
    Mol Pharmacol; 1982 Mar; 21(2):266-71. PubMed ID: 6124875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
    Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
    Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D; Pick CG; Tive LA; Pasternak GW
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.